IL305018A - Methods of producing haemogenic endothelial cells from pluripotent stem cells - Google Patents
Methods of producing haemogenic endothelial cells from pluripotent stem cellsInfo
- Publication number
- IL305018A IL305018A IL305018A IL30501823A IL305018A IL 305018 A IL305018 A IL 305018A IL 305018 A IL305018 A IL 305018A IL 30501823 A IL30501823 A IL 30501823A IL 305018 A IL305018 A IL 305018A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- induction medium
- mesoderm
- population
- fgf
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 78
- 210000002889 endothelial cell Anatomy 0.000 title claims description 6
- 210000001778 pluripotent stem cell Anatomy 0.000 title description 2
- 230000006698 induction Effects 0.000 claims description 42
- 210000003716 mesoderm Anatomy 0.000 claims description 22
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 19
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 17
- 230000004069 differentiation Effects 0.000 claims description 16
- 210000001704 mesoblast Anatomy 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 13
- 230000019491 signal transduction Effects 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 7
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 claims description 6
- 101700032040 SMAD1 Proteins 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 claims description 5
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 claims description 5
- 102100030607 Mothers against decapentaplegic homolog 9 Human genes 0.000 claims description 5
- 101700031501 SMAD9 Proteins 0.000 claims description 5
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 13
- 230000003394 haemopoietic effect Effects 0.000 claims 13
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 12
- 102000036693 Thrombopoietin Human genes 0.000 claims 12
- 108010041111 Thrombopoietin Proteins 0.000 claims 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 12
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 11
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 11
- 102100020880 Kit ligand Human genes 0.000 claims 8
- 101710177504 Kit ligand Proteins 0.000 claims 8
- 210000001978 pro-t lymphocyte Anatomy 0.000 claims 8
- 235000015097 nutrients Nutrition 0.000 claims 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 6
- 108010002386 Interleukin-3 Proteins 0.000 claims 6
- 108090001005 Interleukin-6 Proteins 0.000 claims 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 5
- 108010083359 Antigen Receptors Proteins 0.000 claims 4
- 102000006306 Antigen Receptors Human genes 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 108010033276 Peptide Fragments Proteins 0.000 claims 4
- 102000007079 Peptide Fragments Human genes 0.000 claims 4
- 108091008605 VEGF receptors Proteins 0.000 claims 4
- 108010059616 Activins Proteins 0.000 claims 3
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 3
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 claims 3
- 239000000488 activin Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108091033409 CRISPR Proteins 0.000 claims 2
- 102000001267 GSK3 Human genes 0.000 claims 2
- 108060006662 GSK3 Proteins 0.000 claims 2
- 102000038624 GSKs Human genes 0.000 claims 2
- 108091007911 GSKs Proteins 0.000 claims 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000010362 genome editing Methods 0.000 claims 2
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical group CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 1
- 101150112093 FGF9 gene Proteins 0.000 claims 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 102000050057 Goosecoid Human genes 0.000 claims 1
- 108700031316 Goosecoid Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- -1 Mixll Proteins 0.000 claims 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims 1
- 101100165554 Mus musculus Bmp5 gene Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100021796 Sonic hedgehog protein Human genes 0.000 claims 1
- 101710113849 Sonic hedgehog protein Proteins 0.000 claims 1
- 102100021382 Transcription factor GATA-6 Human genes 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 108010023082 activin A Proteins 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 230000011748 cell maturation Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/051—Lipid A (MPA, MPL)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2311—Interleukin-11 (IL-11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/32—Angiotensins [AT], angiotensinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2102297.5A GB202102297D0 (en) | 2021-02-18 | 2021-02-18 | Methods of Producing Haemogenic Endothelial Cells from Pluripotent Stem Cells |
| PCT/EP2022/053985 WO2022175401A1 (en) | 2021-02-18 | 2022-02-17 | Methods of producing haemogenic endothelial cells from pluripotent stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL305018A true IL305018A (en) | 2023-10-01 |
Family
ID=75339190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305018A IL305018A (en) | 2021-02-18 | 2022-02-17 | Methods of producing haemogenic endothelial cells from pluripotent stem cells |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240124841A1 (https=) |
| EP (1) | EP4294911A1 (https=) |
| JP (1) | JP2024507472A (https=) |
| CN (1) | CN116917465A (https=) |
| AU (1) | AU2022223203A1 (https=) |
| CA (1) | CA3208416A1 (https=) |
| GB (1) | GB202102297D0 (https=) |
| IL (1) | IL305018A (https=) |
| WO (1) | WO2022175401A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201911958D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Methods of t cell production |
| GB202205572D0 (en) | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
| CN115247152B (zh) * | 2022-09-21 | 2022-12-27 | 呈诺再生医学科技(北京)有限公司 | 制备造血干细胞或造血干祖细胞的方法及培养长期再生造血干细胞的方法 |
| CN118360247A (zh) * | 2023-01-19 | 2024-07-19 | 中国科学院动物研究所 | 一种iSCLP细胞及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8652845B2 (en) * | 2010-03-18 | 2014-02-18 | Kyoto University | Method for producing mesodermal cells by culturing under adherent conditions and without co-culture with cells from a different species in a serum-free medium |
| HUE043785T2 (hu) * | 2013-03-13 | 2019-09-30 | Wisconsin Alumni Res Found | Módszerek és anyagok humán pluripotens õssejtek hematoendothelialis differenciálására meghatározott körülmények között |
| US10385313B2 (en) * | 2013-10-01 | 2019-08-20 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Human IPSC-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings |
| WO2015199127A1 (ja) * | 2014-06-24 | 2015-12-30 | 国立大学法人京都大学 | 中胚葉細胞および造血細胞の製造方法 |
| WO2016123100A1 (en) * | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| SG11201803145RA (en) * | 2015-11-04 | 2018-05-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| CN112041428B (zh) * | 2018-01-18 | 2024-05-24 | 新加坡科技研究局 | 用于在悬浮培养物中分化人多能干细胞系的方法 |
| AU2019368313A1 (en) * | 2018-10-24 | 2021-05-20 | Hebecell Corporation | Methods and systems for manufacturing hematopoietic lineage cells |
| GB201911957D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Methods of producing haemogenic progenitor cells from pluripotent stem cells |
| EP4017969A1 (en) * | 2019-08-20 | 2022-06-29 | Adaptimmune Limited | Culture medium for haematopoietic induction |
-
2021
- 2021-02-18 GB GBGB2102297.5A patent/GB202102297D0/en not_active Ceased
-
2022
- 2022-02-17 WO PCT/EP2022/053985 patent/WO2022175401A1/en not_active Ceased
- 2022-02-17 US US18/546,821 patent/US20240124841A1/en active Pending
- 2022-02-17 JP JP2023547485A patent/JP2024507472A/ja not_active Withdrawn
- 2022-02-17 EP EP22707082.8A patent/EP4294911A1/en active Pending
- 2022-02-17 IL IL305018A patent/IL305018A/en unknown
- 2022-02-17 CA CA3208416A patent/CA3208416A1/en active Pending
- 2022-02-17 AU AU2022223203A patent/AU2022223203A1/en not_active Abandoned
- 2022-02-17 CN CN202280015549.0A patent/CN116917465A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240124841A1 (en) | 2024-04-18 |
| EP4294911A1 (en) | 2023-12-27 |
| CN116917465A (zh) | 2023-10-20 |
| WO2022175401A1 (en) | 2022-08-25 |
| CA3208416A1 (en) | 2022-08-25 |
| JP2024507472A (ja) | 2024-02-20 |
| GB202102297D0 (en) | 2021-04-07 |
| AU2022223203A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL305018A (en) | Methods of producing haemogenic endothelial cells from pluripotent stem cells | |
| JP2022545782A5 (https=) | ||
| US8476419B2 (en) | Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination | |
| JP2022545415A5 (https=) | ||
| JP2022545782A (ja) | 多能性幹細胞から造血性前駆細胞を生産する方法 | |
| US20130108663A1 (en) | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination | |
| CN114341349A (zh) | 造血诱导培养基 | |
| JP2024507472A5 (https=) | ||
| CN111004781A (zh) | 长期扩增粒细胞-巨噬细胞祖细胞的方法及其应用 | |
| CN116376822A (zh) | 利用人多潜能干细胞体外制备t淋巴细胞 | |
| EP2201100A1 (en) | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination | |
| US20220249567A1 (en) | Low density cell culture | |
| CN115087732B (zh) | 来自人T细胞来源的iPS细胞的细胞毒性T细胞 | |
| CN108220243A (zh) | 一种多能干细胞及其分化的t细胞和应用 | |
| Lapteva et al. | Optimization manufacture of virus‐and tumor‐specific T cells | |
| US20250375520A1 (en) | Production of immune cells | |
| CN117264887A (zh) | 一种从hiPSCs获得hIL-12分泌型巨噬细胞的方法及应用 | |
| CN118871573A (zh) | 产生Vδ1+T细胞的方法 | |
| JP2024525910A5 (https=) | ||
| Mu et al. | Development of a clinical grade procedure for generation of mRNA transfected dendritic cells from purified frozen CD34+ blood progenitor cells | |
| RU2022107099A (ru) | Культуральная среда для гемопоэтической индукции | |
| CN119912588B (zh) | 嵌合抗原受体、人诱导多能干细胞、髓系前体细胞样巨噬细胞及其制备方法 | |
| Zong et al. | GMP manufacturing of allogenic iPSC-NK cells for immunotherapy | |
| CN117887658A (zh) | 一种人多能干细胞分化为自然杀伤细胞的方法与应用 | |
| KR102134428B1 (ko) | 면역관용을 가지는 유도만능줄기세포 및 이의 제조방법 |